DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Xibrom (Bromfenac Sodium Ophthalmic) - Published Studies

 
 



Xibrom Related Published Studies

Well-designed clinical trials related to Xibrom (Bromfenac Ophthalmic)

Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain. [2011.09]

PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF COMBINATION RANIBIZUMAB (LUCENTIS) AND BROMFENAC (XIBROM) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Pilot Study. [2011.08.20]

Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain. [2011]

Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. [2010.12]

Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. [2009.10]

Comparison of efficacy of bromfenac sodium 0.1% ophthalmic solution and fluorometholone 0.02% ophthalmic suspension for the treatment of allergic conjunctivitis. [2009.06]

Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. [2009.05]

Topical bromfenac 0.09% vs. ketorolac 0.4% for the control of pain, photophobia, and discomfort following PRK. [2009.02]

Ocular pharmacokinetics of a single dose of bromfenac sodium ophthalmic solution 0.1% in human aqueous humor. [2008.12]

Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels. [2008.09]

In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. [2007.09]

Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. [2007.09]

Effects of an opioid (oxycodone/paracetamol) and an NSAID (bromfenac) on driving ability, memory functioning, psychomotor performance, pupil size, and mood. [2006.06]

Well-designed clinical trials possibly related to Xibrom (Bromfenac Ophthalmic)

NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. [2010.02]

Other research related to Xibrom (Bromfenac Ophthalmic)

[Efficacy observation of 0.1% bromfenac sodium eye drops on relieving the post-LASEK irritative symptoms]. [Article in Chinese] [2015]

[Comparison of clinical effects of bromfenac sodium ophthalmic solution 0.1% versus glucocorticoids for post-LASEK usage]. [Article in Chinese] [2015]

Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. [2013]

Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration. [2012]

A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification. [2011.12]

Prostaglandin E(2) Inhibition of Ketorolac 0.45%, Bromfenac 0.09%, and Nepafenac 0.1% in Patients Undergoing Phacoemulsification. [2011.11.18]

Safety and efficacy of bromfenac ophthalmic solution () dosed once daily for postoperative ocular inflammation and pain. [2011.11]

Pharmacokinetic comparisons of bromfenac in DuraSite and Xibrom. [2011.02]

Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK. [2011]

Efficacy and safety of bromfenac for the treatment of corneal ulcer pain. [2010.10]

Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration. [2009.11]

Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent. [2009.10]

Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. [2009.09.02]

Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing. [2009.06]

Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. [2009.01.30]

24-hour evaluation of the ocular distribution of (14)c-labeled bromfenac following topical instillation into the eyes of New Zealand white rabbits. [2008.08]

The systemic safety of bromfenac ophthalmic solution 0.09%. [2007.12]

Corneal melting and perforation in Stevens Johnson syndrome following topical bromfenac use. [2007.09]

Bromfenac Ophthalmic Solution 0.09% (Xibrom) for Postoperative Ocular Pain and Inflammation. [2007.04.18]

Topical bromfenac sodium for long-term management of vernal keratoconjunctivitis. [2007]

Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. [2006.06]

A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. [2006.04]

Other possibly related research studies

Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. [2006.08]

Three cases of corneal melting after instillation of a new nonsteroidal anti-inflammatory drug. [2006.02]

Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. [2006.02]

Effects of topical anti-inflammatory agents in a botulinum toxin B-induced mouse model of keratoconjunctivitis sicca. [2007.02]

Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK). [2007.11]

Topical ocular delivery of NSAIDs. [2008.06]

Cyclooxygenase (COX)-inhibiting drug reduces HSV-1 reactivation in the mouse eye model. [2009.03]

Cytotoxicity of topical medications used for infection and inflammation control after cataract surgery in cultured corneal endothelial cells. [2010.09]

NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. [2010]

Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery. [2013]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017